Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2017—Sysmex America has signed a distribution agreement with Alifax S.r.l. for its erythrocyte sedimentation rate products. The Alifax Test 1 and Roller 20 family of automated analyzers gives ESR results in 20 seconds.
March 2017—EKF Diagnostics previewed a point-of-care connectivity solution for its range of HbA1c analyzers at Medica 2016 in November in Düsseldorf, Germany. Its connectivity package for Quo-Test and Quo-Lab HbA1c analyzers enable secure, bi-directional communication between the POC analyzers and a multitude of central data management systems.
March 2017—Roche announced that its dedicated, high-throughput HbA1c testing solution, the Cobas c 513 analyzer, and HbA1c Gen. 3 assay have received 510(k) clearance from the Food and Drug Administration.
March 2017—Illumina unveiled the NovaSeq series and announced the launch of the Illumina Bio-Rad Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference in January.
March 2017—MDxHealth was awarded a U.S. General Services Administration supply contract to use ConfirmMDx for Prostate Cancer within the Department of Veterans Affairs.
February 2017—Abbott’s i-Stat Alinity System, a handheld blood testing platform, received CE marking and is for sale in Europe and other countries that recognize the CE mark. The portable device can perform and analyze a large menu of blood tests on a single device, ranging from blood chemistries to cardiac markers, using two to three drops of a person’s blood.
February 2017—Hamilton Storage introduced its SAM HD, a low-capacity automated sample management system that aims to be a reliable, walkaway solution for labs seeking to transition from manual to automated sample storage.
February 2017—Genospace launched the Genospace Trial Match, a mobile application that enables real-time clinical trial matching at the point of care based on molecular profiling and clinical data. The app allows leaders in precision medicine to streamline the clinical trial matching process by identifying patients who may qualify for open and enrolling clinical trials.
February 2017—Micromedic Technologies introduced CellDetect, a staining assay for the early detection of bladder cancer in urine specimens, to the U.S. market. The assay uses color and morphology to differentiate between normal and malignant cells.
February 2017—Chi Solutions, an Accumen company, has released a research report that includes the results of its 15th annual comprehensive Outreach Survey, conducted in early 2016.
